Status:
RECRUITING
Hypofraction Radiotherapy for Locally Advanced Non-small Cell Lung Cancer
Lead Sponsor:
Anhui Provincial Hospital
Conditions:
Toxicity Due to Radiotherapy
Non-small Cell Lung Cancer
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
Definitive concurrent chemoradiotherapy followed by durvalumab (Pacific protocol) has been the standard modality for stage III locally advanced non-small cell lung cancer. In spite of the median overa...
Detailed Description
Trial title: Hypofraction radiotherapy followed by immune checkpoint inhibitors for locally advanced non-small cell lung cancer: A phase I/II clinical trial. Trial objective: To explore the safety an...
Eligibility Criteria
Inclusion
- 18-70 years old;
- Eastern Cooperative Oncology Group (ECOG) 0-1;
- Non-small cell lung cancer including squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, large-cell carcinoma;
- Wild-type of driven genes;
- Stage III (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and d Positron Emission Tomography (PET-CT);
- Surgically unresectable or deny of surgery;
- Signature of inform consent.
Exclusion
- Younger than 18 years old or older than 70 years old;
- ECOG\>1;
- Small-cell lung cancer and other neuroendocrine carcinoma including typical or atypical carcinoid, large-cell neuroendocrine carcinoma;
- Mutant type of driven genes;
- Non-stage III (AJCC 8th Edition) confirmed by cranial MRI, chest CT, abdominal ultrasonograph, bone scan or cranial MRI and PET-CT;
- Surgically resectable;
- No signature of inform consent.
Key Trial Info
Start Date :
August 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT05269485
Start Date
August 1 2021
End Date
December 1 2024
Last Update
June 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Anhui Provicial Hospital
Hefei, Anhui, China